Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer by Plenker, D. et al.
Title:  Mechanistic  insight  into  RET kinase  inhibitors  targeting  the  DFG-out
conformation in RET-rearranged cancer
Authors:  D.  Plenker1,2,§,  M.  Riedel1,2,§,  J.  Brägelmann1,2,  M.  A.  Dammert1,2,  R.
Chauhan3,  P.  P.  Knowles3,  C.  Lorenz1,2,  M.  Keul7,  M.  Bührmann7,  O.  Pagel4,  V.
Tischler2, A. H. Scheel5, D. Schütte2, Y. Song6, J. Stark7, F. Mrugalla7, Y. Alber7, A.
Richters7, J. Engel7, F. Leenders8, J. M. Heuckmann8, J. Wolf9, J. Diebold10, G. Pall11,
M. Peifer2, M. Aerts12,13, K. Gevaert12,13, R. P. Zahedi4, R. Buettner5, K. M. Shokat14, N.
Q. McDonald3,15, S. M. Kast7, O. Gautschi10, †, R. K. Thomas2,9,16,† and M. L. Sos1,2,†,* 
Affiliations:
1Molecular  Pathology,  Institute  of  Pathology,  Center  of  Integrated  Oncology,
University Hospital Cologne, 50937, Cologne, Germany. 
2Department  of  Translational  Genomics,  Center  of  Integrated  Oncology  Cologne–
Bonn, Medical Faculty, University of Cologne, 50931, Cologne, Germany.
3Structural  Biology  Laboratory,  Francis  Crick  Institute,  44  Lincoln’s  Inn  Fields,
London WC2A 3LY, UK
4Leibniz-Institut für Analytische Wissenschaften – ISAS – e.V., Dortmund, Germany
5Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne,
50937, Cologne, Germany.
6Crown Bioscience, Inc. 3375 Scott Blvd, suite 108, Santa Clara, CA 95054, USA.
7Faculty  of  Chemistry  and  Chemical  Biology,  TU  Dortmund  University,  44227,
Dortmund, Germany.
8NEO New Oncology GmbH, 51105, Cologne, Germany.
9Department  of  Internal  Medicine,  Center  for  Integrated  Oncology  Köln-Bonn,
"THIS PDF IS AUTOMATICALLY GENERATED AND MAY HAVE 
FORMATTING ERRORS. THE AUTHOR-PROVIDED FILES ARE 
AVAILABLE IN THE MANUSCRIPT DOCUMENTS TAB." 
University Hospital Cologne, Cologne, 50931, Cologne, Germany.
10Cancer Center, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland
11Department  of  Internal  Medicine  5,  University  Hospital  Innsbruck,
Hematology/Oncology, Anichstraße 35, 6020 Innsbruck, Austria
12VIB-UGent Center for Medical Biotechnology, VIB, B-9000 Ghent, Belgium
13Department of Biochemistry, Ghent University, B-9000 Ghent, Belgium
14Department  of  Cellular  and  Molecular  Pharmacology,  Howard  Hughes  Medical
Institute, University of California, San Francisco, CA 94158, USA
15Institute of Structural and Molecular Biology, Department of Biological Sciences,
Birkbeck College, Malet Street, London WC1E 7HX, UK
16German  Cancer  Consortium  (DKTK),  partner  site  Heidelberg  and  German
Cancer Research Center (DKFZ), Heidelberg, Germany 
* To whom correspondence should be addressed:  
Martin L. Sos; martin.sos@uni-koeln.de
§ These authors contributed equally to this work
† These authors contributed equally to this work
One Sentence Summary: 
Our work provides mechanistic insights into the activity profiles of RET inhibitors
that bind in the DFG-out conformation of RET and may be of importance for the
effective treatment of RET-rearranged cancers.
Abstract
Oncogenic fusion events have been identified in a broad range of tumors. Among
them, RET rearrangements represent distinct and potentially druggable targets
that are recurrently found in lung adenocarcinomas. Here, we provide further
evidence  that  current  anti-RET drugs  may  not  be  potent  enough  to  induce
durable responses in such tumors. We report that potent inhibitors such as AD80
or  ponatinib  that  stably  bind  in  the  DFG-out  conformation  of  RET  may
overcome these limitations and selectively  kill  RET-rearranged tumors.  Using
chemical  genomics  in  conjunction  with  phosphoproteomic  analyses  in  RET-
rearranged  cells  we  identify  the  CCDC6-RETI788N mutation  and  drug-induced
MAPK  pathway  reactivation  as  possible  mechanisms,  by  which  tumors  may
escape the activity of RET inhibitors. Our data provide mechanistic insight into
the druggability of RET kinase fusions that may be of help for the development
of effective therapies targeting such tumors.
Introduction
Targeted inhibition of oncogenic driver mutations with small molecules represents the
cornerstone of precision cancer medicine. RET rearrangements have been identified in
a broad range of tumors including 1-2% of lung adenocarcinomas and their discovery
sparked the hope for an effective treatment option in these patients  (1-3). However,
when  compared  to  other  oncogenic  "driver"  alterations  such  as  rearranged  ALK,
rearranged RET seems to represent a difficult  target as to  date,  no drug has been
successfully established for the treatment of these tumors (4-6). Recent clinical data
suggest that overall response rates in patients treated with currently available RET
targeted drugs are rather limited and range between 18% - 53%  (7-10).  Improved
selection  of  patients  based on deep sequencing of  individual  tumors  may help to
increase  these  response  rates  but  still  progression-free  survival  seems to  be  very
limited (8-11). These observations are particularly surprising from a chemical point of
view since a broad spectrum of kinase inhibitors is known to bind to RET and to
inhibit its kinase activity in vitro.
Based on these  observations  we sought  to  characterize  rearranged RET in
orthogonal cancer models to identify potent RET inhibitors with high selectivity and
optimal biochemical profile to target RET-rearranged tumors. 
Results
Kinase inhibitor AD80 shows extraordinary activity in  RET-rearranged cancer
models
Since clinical experience with RET targeted drugs in lung cancer patients is rather
disappointing we sought to test a series of clinically and preclinically available drugs
with anti-RET activity  in  Ba/F3 cells  engineered to  express either  KIF5B-RET or
CCDC6-RET (1, 2, 12, 13). In these experiments, AD80 and ponatinib exhibited 100-
to 1000-fold higher cytotoxicity compared to all other tested drugs in RET-dependent,
but not IL-3 supplemented Ba/F3 cells  (Fig. 1A; Fig.  S1A,B).  In line with these
results, AD80, but not cabozantinib or vandetanib prevented phosphorylation of RET
as well as of ERK, AKT and S6K at low nanomolar concentrations in  KIF5B-RET
expressing Ba/F3 cells (Fig. 1B, Supplementary Table 1).
To validate the efficacy of AD80 and ponatinib in an orthogonal model, we
induced KIF5B-RET rearrangements (KIF5B exon 15; RET exon 12) in NIH-3T3 cells
using  CRISPR/Cas9-meditated  genome  editing.  We  confirmed  their  anchorage-
independent growth, increased proliferation rate and their high sensitivity to AD80
and  ponatinib  (Fig.  1C;  Fig.  S1C-E)  (14). Again,  treatment  with  AD80  but  not
cabozantinib  or  vandetanib  led  to  inhibition  of  phospho-RET and of  downstream
effectors of RET signaling at low nanomolar concentrations (Fig. 1D). Interestingly,
AD80 led to dephosphorylation of S6 also in parental NIH-3T3 cells and Ba/F3myr-AKT
control  cells  suggesting  that  S6  may  represent  an  off-target  at  micromolar
concentrations (Fig. 1D; Fig. S1F) (12).
To further substantiate our results, we next tested our panel of RET inhibitors
in  the  CCDC6-RET rearranged lung adenocarcinoma cell  line  LC-2/AD  (15). We
observed similar activity profiles with AD80 followed by ponatinib as the most potent
inhibitors compared to all other tested drugs in terms of cytotoxicity at low nanomolar
concentrations  (Fig.  1E) and  inhibition  of  phospho-RET  and  other  downstream
signaling molecules (Fig. 1F). 
Overall, our data suggest that in RET-rearranged cells AD80 and ponatinib are
100- to 1000-fold more effective against RET and its downstream signaling than any
other clinically tested anti-RET drug.
Highly specific and effective inhibition of RET fusions in DFG-out conformation
To benchmark the  genotype-specific  activity  of  AD80 and ponatinib  against  well
described  kinase  inhibitors  such  as  erlotinib,  BGJ398,  vandetanib,  cabozantinib,
regorafenib, alectinib and ceritinib in a panel of 18 cancer cell lines driven by known
oncogenic lesions such as mutant  EGFR or rearranged ALK,  including two  RET-
rearranged cells (LC-2/AD and TPC-1) (Fig. S2A)  (6, 13, 16). Again, we identified
AD80 and ponatinib as the most effective drug and through the calculation of median
on-target vs. off-target ratios also as the most specific drugs in  RET-fusion positive
cells (Fig. S2B; Supplementary Table 2). 
To further characterize intracellular signaling induced by a RET-inhibitor like
AD80 we performed mass-spectrometry  based phosphoproteomic  analyses  of  LC-
2/AD cells treated with 10nM or 100nM of AD80. In AD80 treated cells we observed
a significant decrease of RET-Y900 phosphorylation with log2-fold changes of -1.07
(p=0.009; 10nM AD80) and -2.11 (p=0.0002; 100nM AD80), respectively (Fig. 2A).
Among all phospho-peptides quantified under control, 10nM and 100nM conditions
(n=11912),  the  abundance  of  RETY900 was  among  the  most  decreased  phospho-
peptides (ctrl. vs 100nM AD80; p=0.00024) and the most decreased receptor tyrosine
kinases  (Fig.  S2C). These results  highlight  that  in these cells  RET is the primary
target of AD80.
Based  on  these  observations,  we  speculated  that  activation  of  RET-
independent  signaling  pathways  should  largely  abrogate  the  cytotoxic  effects  of
AD80. To this end we supplemented LC-2/AD cells with exogenous receptor ligands
and found that activity of AD80 was significantly reduced through addition of EGF,
HGF and NRG1 indicating that RET is indeed the primary cellular target in  RET-
rearranged LC-2/AD cells (Fig. S3A).
To further characterize the high potency of AD80 and ponatinib against RET
kinase fusions we expressed and purified different truncated versions of the RET core
kinase and juxtamembrane-kinase domain as well as truncated forms of both CCDC6
(∆CCDC6-KD) or KIF5B (∆KIF5B-KD) kinase domain fusions (Fig. S3B,C)  (17).
We used these different RET-fusion kinase domain constructs to determine the extent
to which binding of a given compound has an effect on protein thermal stability as
measured by the melting temperature (Tm). The difference of melting temperature
with and without drug (∆Tm) extrapolates the potency of the individual drugs against
the respective constructs (17). To our surprise, we found that treatment with the type I
inhibitors sunitinib or vandetanib resulted in a ∆Tm of only 1-4°C whereas the type II
inhibitors sorafenib, ponatinib or AD80 increased the ∆Tm up to 10-18°C (Fig. 2B;
Fig. S3D-H). We observed the strongest effects in ∆KIF5B-KD and ∆CCDC6-KD
constructs  treated  with  AD80  and  core  KD  with  ponatinib  (Fig.  2B;  Fig.  S3D;
Supplementary Table 3). Interestingly, this strong shift for inhibitors that stabilize
the  DFG-out  conformation  does  not  correlate  with  the  differential  in  vitro kinase
activity observed for sorafenib and other RET inhibitors  (Supplementary Table 4)
(6).
To further characterize the relevance of a DFG-out conformation for the activity of
RET inhibitors we performed structural analyses. We employed homology modelling
based on a VEGFR kinase (pdb code 2OH4 (18)) in the DFG-out complex, followed
by extensive molecular dynamics (MD) simulation refinement, similar to a previously
published methodology (19). We observed that the RMSD values remained largely
stable over the time course of the MD simulation (RET-wt and RET-V804M) thus
supporting our proposed model in which AD80 binds in the DFG-out conformation of
the kinase (Fig. S4A). In this model AD80 forms an H-bond between the aspartate of
the DFG motif that may be involved in the stabilization of the DFG-out conformation
(Fig.  3A).  A similar  H-bond  is  also  observed  for  cabozantinib, a  known  type  II
inhibitor, bound  to  RET-wt  (Fig.  S4B,  see  Supplementary  Methods for  model
generation). This finding corroborates the validity of our binding mode hypothesis,
though the pose is biased by construction, being based on the refined RET-wt/AD80
structure. Furthermore, we developed a binding pose model for AD57 (derivative of
AD80)  bound  to  RET-wt  (see  below)  which,  upon  superimposition,  displays
considerable similarity with the experimentally determined structure of AD57 bound
to cSrc (PDB code 3EL8) in the DFG-out form, again validating our approach (Fig.
S4C, Fig. S3H). Next we performed free energy MD simulations to transform AD80
into AD57. The calculations yield a binding free energy difference of ΔΔG° = -0.21 ±
0.17 kcal mol-1 at 25°C, which compares well with the values derived from IC50 in in
vitro kinase measurements. These latter concentration-based measures of binding
affinity  translate  into  an  experimental  estimate  of  the  binding  free  energy
difference of -0.41 kcal mol^-1 with IC50(AD57) of 2nM and IC50(AD80) of 4nM (see
Supplementary  methods)  (12).  Using as  an  alternative  computational  approach an
integral  equation  approximation  (see  Supplementary  Methods)  we obtain  0.1  kcal
mol-1,  also in close correspondence with both MD and experimental results.  Thus,
these analyses further support the proposed DFG-out conformation as the preferred
binding mode since such agreement between experiment and theory would not have
been expected if the true and predicted binding modes were largely dissimilar.
Overall, our cellular screening, phosphoproteomic, biochemical and structural
data indicate that potent type II inhibitors like AD80 or ponatinib have an optimal
RET specific profile that distinguishes them from currently available anti-RET drugs.
Differential activity of RET inhibitors against RET kinase gatekeeper mutation
Secondary  resistance  mutations  frequently  target  a  conserved  residue,  termed
gatekeeper that controls access to a hydrophobic subpocket of the kinase domain (20).
To  test  the  impact  of  the  gatekeeper  resistance  mutations  on  RET inhibitors  we
established Ba/F3 cells expressing  KIF5B-RETV804M or  CCDC6-RETV804M and tested
them against a panel of different drugs. As expected only ponatinib but also AD80
showed high activity in these gatekeeper mutant cells (Fig. 3B) (21). Similar activity
was observed when testing the AD80 derivatives AD57 and AD81 for their inhibitory
potential on Ba/F3 cells expressing wild type and V804M mutated  KIF5B-RET or
CCDC6-RET (Fig. S5A). This effect was also evident in the ability of AD80 to inhibit
phosphorylation of RET as well as of ERK, AKT and S6K in these cells  (Fig. 3C,
Supplementary  Table  S1).  Next,  we  used  computational  homology  modeling
coupled with MD refinement of AD80 in RETwt in comparison with RETV804M-mutant
kinases.  In  line  with  our  in  vitro results, this  analysis revealed  high  structural
similarity and similar binding free energy estimates for both variants (-2.5 kcal mol-1
for transforming RETwt to RETV804M bound to AD80 from the integral equation model)
(Fig. 3A, Supplementary Methods). 
In  parallel,  we  noticed  that  independent  of  the  individual  treatment,  RET
phosphorylation levels tended to be higher in gatekeeper mutant cells when compared
to wild type RET (Fig. 3D). To further characterize these differences we performed in
vitro kinase  assays  and  found  that  the  introduction  of  the  RETV804M mutation
significantly (p<0.001)  increases the  affinity  of  the  recombinant  receptor  for ATP
when compared to the recombinant wild type receptor (Fig. 3E). 
Thus,  similar  to  gatekeeper-induced  effects  on  ATP affinity  observed  for
EGFRT790M mutations, our data suggests that these effects may be of relevance for the
activity of RET inhibitors in KIF5B-RETV804M and CCDC6-RETV804M cells (22).
Saturated  mutagenesis  screening  identifies  novel  CCDC6-RETI788N drug
resistance mutation
To identify novel RET kinase mutations that may be associated with resistance against
targeted therapy we performed accelerated mutagenesis of RET-fusion plasmids (23,
24). We identified the  CCDC6-RETI788N mutation by selection of an AD80 resistant
cell  population  (Supplementary Table 5).  To validate  this  finding we engineered
Ba/F3 cells expressing  KIF5B-RETI788N or  CCDC6-RETI788N and, in fact, observed a
robust shift in cytotoxicity in response to AD80 treatment  (Fig. 4A), as well as the
other  RET inhibitors  cabozantinib,  vandetanib  but  not  ponatinib  (Fig.  4B,C;  Fig.
S5B). Immunoblotting  confirmed  that  the  introduction  of  the  KIF5B-RETI788N
mutation had a minor effect on the efficacy of ponatinib but a major impact on AD80
as measured by phospho-RET levels (Fig. 4D). Computational binding mode analysis
(Fig. 3C and 4E) suggests that both positions 804 and 788 are adjacent to the location
of AD80’s central phenyl ring; characteristic distances between phenyl center of mass
and nearest adjacent protein non-hydrogen sites are 4.77 Å to Val804-C(wt), 3.90 Å to
Ile788-C(wt),  4.29  Å  to  Met804-S(V804M),  and  4.61  Å  to  Ile788-C(V804M).
However,  since  V804M and I788N mutants  respond differently  to  AD80,  a  clear
conclusion about  the  molecular  origin  is  not  possible  based on structural  analysis
alone, requiring further investigations.
Thus, our data uncover a novel resistance mutation RETI788N that may arise in
RET-rearranged  tumors  under  RET inhibitor  treatment  and that  retains  sensitivity
against ponatinib.
Feedback-induced  activation  of  MAPK  signaling  modulates  activity  of  RET
inhibitors
Beyond the acquisition of secondary mutations drug treatment of cancer cells may
also lead to the release of feedback loops that override the activity of targeted cancer
treatment  (25, 26). To systematically characterize these effects we analyzed altered
gene expression by RNA-sequencing of LC-2/AD cells under AD80 treatment and
performed gene  set  enrichment  analysis  (GSEA)  (27). Our  analyses  revealed  that
treatment with AD80 lead to upregulation of genes that are typically repressed by
active KRAS (KRAS down; adj. p<0.0001). On the contrary, genes that are known to
be  activated  by  KRAS were  downregulated  (KRAS up;  adj.  p=0.003)  (Fig.  5A).
Accordingly,  the  list  of  significantly  downregulated genes  contained  DUSP6 (adj.
p<1x10-250),  SPRY4 (adj.  p=5.75x10-89),  DUSP5 (2,52x10-38) and other genes that are
known  to  buffer  MAPK  pathway  (Fig.  5B). This  transcriptional  deregulation  of
MAPK  signaling  was  accompanied  by  residual  phospho-ERK  staining  in
immunoblotting  analyses  of  RET-rearranged LC-2/AD cells  after  24h  of  inhibitor
treatment (Fig. S5C). Using a Group-based Prediction System (GPS 2.12) to identify
kinase  specific  phospho-sites  that  are  perturbed  in  AD80  treated  LC-2/AD  cells
assessed in our mass-spectrometry based analysis we identified a striking enrichment
of phospho-sites known from different families of non-canonical MAPK kinases, such
as  MAPK8  (66  phospho-sites)  MAPK13  (21  phospho-sites)  or  MAPK12  (15
phospho-sites) (Fig. 5C).
We next tested the relevance of RAS-MAPK pathway reactivation in  RET-
rearranged cells and treated with either AD80 alone or a combination of AD80 and the
MEK inhibitor trametinib. In TPC-1 cells with limited vulnerability to RET inhibition
we observed a pronounced phospho-ERK signal in cells after inhibition with AD80
when  compared  to  LC-2/AD  cells (Fig.  S5D).  The  combination  of  AD80  and
trametinib fully abrogated MAPK signaling and depleted outgrowth of resistant cells
in clonogenic assays and enhanced reduction of viability (Fig. 5D and Fig. S5E,F). 
To formally test the relevance of MAPK pathway activation in the context of
resistance to RET targeted therapies in  RET-rearranged cells, we stably transduced
LC-2/AD cells with lentiviral KRASG12V. Indeed, introduction of the oncogenic KRAS
allele into LC-2/AD cells largely eliminated activity of AD80 as measured in viability
assays and by staining of phospho-ERK (Fig. 5E,F).
Overall,  our  data  suggest  that  drug-induced  transcriptional  and  post-
translational reactivation of RAS-MAPK signaling may modulate the activity of RET
targeted inhibitors in RET-rearranged cells. 
AD80 potently shrinks RET-rearranged tumors in patient-derived xenografts
To compare the in vivo efficacy of AD80 head-to-head with other RET inhibitors we
engrafted  NIH-3T3  cells  driven  by  CRISPR/Cas9-induced  KIF5B-RET
rearrangements into NSG mice. After development of tumors, mice were treated with
either vehicle or 12.5 to 25mg/kg of AD80, cabozantinib or vandetanib and tumors
were  explanted  4  hours  later  (28,  29). We  observed  a  pronounced  reduction  of
phosphorylation of RET as well as AKT and ERK in tumors treated with 25mg/kg
AD80,  but  not  in  tumors  treated  with  cabozantinib  or  vandetanib  (Fig.  6A).
Encouraged  by  these  results,  we  next  treated  a  cohort  (n=16)  of  patient-derived
xenograft (PDX) mice engrafted with tumor tissue from a  CCDC6-RET rearranged
colorectal  cancer  (CRC)  patient  either  with  vehicle  or  with  25mg/kg  of  AD80.
Treatment with AD80 induced significant (p<0.001) tumor shrinkage in CCDC6-RET
PDXwt (Fig. 6B,C; Fig. S6A)  (30). In line with our  in vitro data of cells harboring
RET gatekeeper mutations, tumor shrinkage (p<0.01) was robust but less pronounced
when we treated PDX mice (n=16) engrafted with CRC tissue that had developed a
CCDC6-RETV804M gatekeeper  mutation  under  ponatinib  treatment  (Fig.  6B,D;  Fig.
S6B)  (31). Consequently,  we observed a  robust  reduction  of  cellular  proliferation
(CCDC6-RET wt:  p<0.001;  V804M:  p<0.05)  as  measured  by  KI-67  staining  in
CCDC6-RETwt and  CCDC6-RETV804M tumors  (Fig.  6E,F).  Of  importance,  AD80
treatment did not lead to body weight loss in both PDX models over the course of the
study  (Fig. S6C,D). Taken together our data indicate that AD80 represents a highly
potent RET inhibitor with a favorable pharmacokinetic profile in clinically relevant
RET fusion driven tumor models.
Discussion
Our chemical-genomic  and chemical-proteomic  analyses  revealed three  interesting
findings with major implications for the development of effective therapies against
RET-rearranged tumors: i)  RET-rearranged tumors show exquisite vulnerability to a
subset of type II inhibitors that target the DFG-out conformation of RET kinase, ii)
compound specificity and compound activity  can be  only faithfully determined in
orthogonal  in  vitro and  in  vivo models  of  rearranged  RET  and  iii)  resistance
mechanisms against targeted inhibition of RET may involve  RETI788N mutations and
the reactivation of MAPK signaling.
The repurposing of crizotinib for the targeted treatment  of  ALK-rearranged
tumors enabled a fast-track introduction of precision cancer medicine for this group of
cancer patients and raised hopes that this approach may be a blueprint for the targeted
treatment  of  other  driver  oncogenes,  such  as  RET  (32). Although  initial  clinical
response rates were promising in selected patients, a median progression-free survival
of less than 6 months and response rates of only about 18% in retrospective studies
indicated that RET may be a difficult drug target after all (7-9, 33). These data are in
line  with  our  own  retrospective  analysis  where  out  of  four  patients  with  RET-
rearranged tumors we observed only one PR in a patient receiving vandetanib (P2) as
first-line treatment (Fig. S7, Supplementary Table 6A,B). Interestingly, sequencing
of rebiopsy samples did not reveal candidate drug resistance mutations, suggesting
that  the  target  had  been  insufficiently  inhibited  (Supplementary  Methods;
Supplementary Table 6C).
Our systematic  characterization  of  anti-RET drugs revealed unique  activity
and specificity profiles for the type II kinase inhibitors AD80 and ponatinib across
orthogonal  in vitro and  in vivo models across different lineages of  RET-rearranged
cancer.  This  finding  is  noteworthy,  since  the  biochemical  profiling  of  these
compounds  and  structurally  related  compounds  would  have  suggested  a  broad
spectrum of  kinase  targets  (12,  34,  35).  Our  data  also  suggest  that  a  tight  RET
inhibitor binding in the DFG-out conformation of RET as measured by thermal shift
assays only partially tracks with potent  in vitro kinase activity and that an optimal
combination of both drug target interactions may open up a unique opportunity for an
effective inhibition of RET signaling. It remains to be seen how much drug residence
time or structural kinetics that capture additional features of drug target interactions
may contribute to the overall activity of type II inhibitors like sorafenib and other
RET inhibitors (19, 36).
Of note, we identify a novel CCDC6-RETI788N resistance mutation that renders
a number of tested RET inhibitors ineffective while  retaining vulnerability against
ponatinib.  These  findings  resemble  the  experience  with  ALK  inhibitors  in  ALK-
rearranged tumors where the availability of potent inhibitors allows a mutant specific
selection  of  inhibitors  to  overcome  drug  resistance  (37).  In  addition,  our  results
suggest that the reactivation of intracellular networks including MAPK signaling may
contribute to drug tolerance and over time may modulate the efficacy of RET kinase
inhibitors in  RET-rearranged tumors.  Given the  evident  clinical  need for effective
targeted drugs against RET our results provide a strong rationale for optimization of
current  therapeutic  strategies  and  development  of  RET inhibitors  for  an  effective
treatment of RET-rearranged cancers. 
Materials and Methods
CRISPR/Cas9
CRISPR technology was used via a pLenti vector containing Cas9-IRES-blasticidine
and two U6 promoters  for  expression  of  individual  sgRNAs (sgRNA1 (intron  15
murine  KIF5B): GGCACCAAACACTTCACCCC;  sgRNA2 (intron 11 murine  RET):
GGGTGTAGCGAAGTGTGCAT)  (14). 24  hours  after  transfection  the  media  was
changed to media supplemented with blasticidine (10µg/ml) (Life Technologies) for 4
days.
Immunoblot analyses
Immunoblot analyses were performed as previously described  (38). The individual
antibodies  are  specified  in  the  Supplementary  Data.  Detections  of  proteins  was
performed via horseradish peroxidase or via near-infrared fluorescent antibodies using
a LI-COR Odyssey® CLx imaging system.
Phosphoproteomic analyses
LC-2/AD  cells  were  treated  with  0,  10  or  100  nM  AD80,  lysed,  proteolytically
digested with Trypsin and labeled with an Isobaric Mass Tag (TMT10plex, Thermo
Fisher Scientific). Peptides for global proteome analysis were fractionated by high-pH
reversed phase chromatography. Phosphopeptides were enriched via TiO2 beads and
fractionated  using  hydrophilic  interaction  chromatography  (39). Fractions  were
analyzed  by  nano  LC-MS/MS  on  a  Q-Exactive  HF  mass  spectrometer  (Thermo
Scientific)  and  data  were  analyzed  using  the  Proteome  Discoverer  1.4  software
(Thermo Scientific).
Protein Thermal Shift assay
Different variants of RET kinase domain were designed and ordered from Geneart
(Life Technologies). RET variants were expressed in SF21 cells and harvested 72h
post  transfection.  Subsequently  proteins  were  purified  and  phosphorylated.  For
determining the protein thermal shift protein variants were incubated with DMSO or
1µM  compound.  Sypro-Orange  dye  (Life  Technologies)  was  added  to  each  drug
treatment and thermal shift was measured in a 7500 Fast RT PCR machine (Applied
Biosystems) in a temperature range of 25 – 90°C. Subsequent analysis was performed
using Protein Thermal Shift Software v1.2 (Applied Biosystems).
Computational binding mode modeling
Briefly, the VEGFR was taken as template for modeling and filling of sequence gaps,
representing the relevant part of the wt RET protein. All ligand-bound models were
created  by  superpositioning  followed  by  extensive  MD  simulations  and  energy
minimization  to  relax  the  structures  (RETwt/AD80,  RETV804M/AD80,
RETwt/Cabozantinib).  For  comparison with experimentally  determined IC50 ratios,
the binding free energy difference between RETwt/AD80 and RETwt/AD57 was further
estimated  by  MD  simulations  and  integral  equation  calculations  (40),  the  latter
approach was also used for approximate determination of the impact of the V804M
mutation on the binding affinity of AD80. A detailed description can be found in the
supplementary methods section.
ATP binding constant determination
ATP Km determination  for  RET wt  and V804M mutant  was performed using  the
HTRF  KinEASE-TK  assay  (Cisbio)  according  to  manufacturer’s  instructions.  To
determine  ATP  Km,  wt  and  V804M  mutant  were  incubated  with  different  ATP
concentrations  (300µM  - 1.7nM)  for  20min  (RETwt)  and  15min  (RETV804M).
Phosphorylation of the substrate peptide was determined by FRET between europium
cryptate and XL665. ATP Km (app) was calculated using a Michaelis-Menten plot. 
PDX
Tumor  fragments  from  stock  mice  inoculated  with  CCDC6-RET fusion  positive
patient-derived tumor tissues were harvested and used for inoculation into BALB/c
nude mice. Mice were randomly allocated into vehicle and AD80 (25mg/kg) treated
groups when the average tumor volume reached 100-200mm3.  Tumor volume was
measured  twice  weekly  in  two  dimensions  using  a  caliper,  and  the  volume  is
expressed in mm3 (TV = 0.5 a × b2, a/b represent long and short diameter).
Immunohistochemistry
Immunohistochemistry  was performed on Leica  Bond automated  staining  systems
suing  Ki-67  and  Mib-1  (Dako)  antibodies  according  to  the  manufacturer's
instructions. Ki-67 labeling index was determined by manually counting 100 tumor
cells in the area of the highest proliferation.
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Figures
Figure 1
A)  Dose-response  curves  (72h)  as  assessed  for  AD80,  cabozantinib  (CAB),
vandetanib (VAN), alectinib (ALE), regorafenib (REG), sorafenib (SOR), ponatinib
(PON),  crizotinib  (CRI),  ceritinib  (CER)  or  PF06463922  (PF06)  in  KIF5B-RET
expressing Ba/F3 cells.  B) Immunoblotting results of  KIF5B-RET rearranged Ba/F3
cells after treatment are displayed (4h). C) Relative mean colony number of NIH-3T3
cells engineered with KIF5B-RET fusion via CRISPR/Cas9 was assessed in soft agar
assays after 7 days under treatment. Representative pictures of colonies under AD80
treatment  are  depicted  in  the  lower  panel.  Black  bar  is  equal  to  100µm.  D)
Immunoblotting  of  treated  CRISPR/Cas9  engineered  KIF5B-RET-rearranged  NIH-
3T3 cells with AD80, cabozantinib or vandetanib (4h). KIF5B-RET expressing Ba/F3
cells (Ba/F3 ctrl.) serve as control for RET signaling. E) Dose-response curves (72h)
as assessed for different inhibitors in LC-2/AD cells are shown.  F) Immunoblotting
was performed in LC-2/AD cells treated with AD80, cabozantinib or vandetanib (4h).
Figure 2
A)  Scatter plot of log2-fold phosphorylation change for LC-2/AD cells treated (4h)
with  either  10nM  or  100nM  AD80.  Each  dot  represents  a  single  phospho-site;
phospho-RET (Y900) is highlighted in red.  B)  Difference in melting temperatures
after AD80, sorafenib (SOR), vandetanib (VAN) or sunitinib (SUN) addition (ΔTm)
and the respective standard errors of the mean (SEM) are shown for each construct.
Thermal shift experiments were performed using independent preparations of each
protein and were carried out in triplicates (left panel). Representative thermal melting
curves for ΔKIF5B-KD incubated with either AD80 (1μM) or the equivalent volume
of DMSO (ctrl.) are shown (right panel).
Figure 3 
A)  Optimized  structures  after  extensive  MD  refinement  followed  by  ALPB
optimization. (I) RET-wt/AD80 after 102 ns, (II) RET-wt/AD57 after 202 ns (92 ns
from RET-wt/AD80 simulation followed by 110 ns TI-MD), (III) RET-V804M/AD80
after 107 ns (side view). The DFG motif is shown in violet.  Distances from central
phenyl’s  center: 4.77  Å to  Val804-C(wt),  3.90  Å  to  Ile788-C(wt)  and 4.29  Å  to
Met804-S(V804M).  Dashed lines  indicate  the  marked H-bond between the  bound
ligands and aspartate of the DFG motif. B) Heatmap of mean GI50-values (from n≥3)
of Ba/F3 cells expressing CCDC6-RETV804M or KIF5B-RETV804M after 72h of treatment
as assessed for various inhibitors is shown. C) Immunoblotting of AD80, cabozantinib
or  vandetanib  treated  (4h)  KIF5B-RETV804M Ba/F3  cells  is  displayed.  D)
Immunoblotting of Ba/F3 cells expressing  CCDC6-RET-RETwt or  CCDC6-RETV804M
under AD80 or vandetanib treatment (4h). E) Calculated Km values of ATP binding to
RETwt or RETV804M-mutant from three independent experiments are displayed. ***,
p<0.001.
Figure 4
A) Dose-response curves as assessed for AD80 against Ba/F3 cells expressing KIF5B-
RETwt (black) or KIF5B-RETI788N (red) and CCDC6-RETwt (black dashed) or CCDC6-
RETI788N (red dashed).  B)  Column chart  of  mean GI50-values + SD (from n=3) of
KIF5B-RETwt  or KIF5B-RETI788N Ba/F3 cells treated (72h) with AD80, cabozantinib
(CAB),  vandetanib  (VAN)  or  ponatinib  (PON).  p-values  are  given  as  ”*”.  C)
Immunoblotting  of  KIF5B-RETwt  (left  panel)  or  KIF5B-RETI788N  (right  panel)  and
CCDC6-RETwt  or CCDC6-RETI788N  (lower panel) Ba/F3 treated (4h) with AD80 are
displayed  (4h).  D) Immunoblotting  of  KIF5B-RETwt,  KIF5B-RETV804M or  KIF5B-
RETI788N Ba/F3 cells treated (4h) with ponatinib are shown. HSP90 is used as loading
control.  E) Optimized structure after extensive MD refinement followed by ALPB
optimization. RET-wt/AD80 after 102 ns (side view). Distance from central phenyl’s
center: 4.61 Å to Ile788-C(V804M).
Figure 5 
A) RNA-Seq results of LC-2/AD cells treated (48h) with 100nM AD80 are shown.
Genes contained within the core enrichments following GSEA against the hallmark
gene sets  with genes upregulated (KRAS up) or downregulated (KRAS down) by
active  KRAS  are  highlighted  by  red  and  green,  respectively.  The  dashed  line
represents  FDR-adjusted q-value= 0.05.  B) Relevant  genes from the  top-50 genes
with strongest and significant change in RNAseq after AD80 treatment (100nM/48h)
are shown. C) The predicted number of down regulated phosphorylation sites for each
kinase is shown. All kinases with ≥6 down regulated phosphorylation sites are shown
in  hierarchical  order.  Kinases  associated  with  MAPK  pathway  signaling  are
highlighted in red. D) In immunoblotting assays RET signaling was monitored in LC-
2/AD and TPC-1 cells, treated (48h) with either AD80 (0.1µM), trametinib (TRA)
(0.1µM) or a combination of both inhibitors (combo). E) LC-2/ADev or LC-2/ADKRAS
G12V  cells were treated (72h) with AD80. Results are shown as mean + SD (n=3).  p-
values given as ”*” are displayed. F) Immunoblotting of LC-2/ADev or LC-2/ADKRAS
G12V cells under AD80 treatment (100nM/4h) is shown.
Figure 6 
A)  Immunoblotting  of  tumor  tissue  from  CRISPR/Cas9  induced  NIH-3T3KIF5B-RET
Xenografts was performed. Mice were treated (4h) with vehicle control, 12.5 or 25
mg/kg AD80, CAB or VAN and sacrificed.  B) Median tumor volume was assessed
using consecutive measurements of patient-derived xenograft (PDX) tumors driven by
CCDC6-RETwt or  CCDC6-RETV804M rearrangements under treatment  with either 25
mg/kg AD80 (14d) or vehicle-control (14d). Treatment starts at day 0.  C) Waterfall
plot for each CCDC6-RETwt fusion positive PDX depicting best response (14d) under
AD80 or vehicle-control treatment is displayed. ***,  p<0.001. D) Waterfall plot for
each  CCDC6-RETV804M positive  PDX depicting best  response (7d) under  AD80 or
vehicle-control treatment is displayed. ***, p<0.001. E) Representative IHC stainings
for H&E and Ki-67 of AD80 or vehicle control treated CCDC6-RETwt derived PDX.
Scale bar represents 100 µm. F) Ki-67 IHC staining and the plotted values are shown.
***, p<0.001.
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Methods 
Study population 
All patients consented to testing, therapy and registration of data for future 
publication. RET FISH testing was performed by experienced pathologists (RB, JD) 
as described before (33). All tumors were negative for coexisting mutations of EGFR, 
ALK, ROS1, HER2 or BRAF. Rebiopsies of P1 and P2 were sequenced using hybrid 
capture-based next-generation sequencing (NEO, New Oncology AG). Available 
RET inhibitors were given off-label (sunitinib, vandetanib) or compassionate use 
(cabozantinib) in accordance with local regulations. Follow up was performed by PET 
or CT scans in intervals of 2-4 weeks, and interpreted by radiologists. Response rates 
were measured according to RECIST 1.1 criteria. 
 
Antibodies used for immunoblot 
The following antibodies were obtained from Cell Signaling: p-AKT Ser473 (Catalog 
No. #9271), p-ERK1/2 Thr202/Tyr204 (Catalog No. #4370), p-S6 Ser235/236 
(Catalog No. #4858), p-RET Tyr905 (Catalog No. #3221), AKT (Catalog No. #9272), 
ERK 1/2 (Catalog No. #9102), S6 (Catalog No. #2217), RET (Catalog No. #3220). 
HSP90 (#SPA-835) was purchased from Enzo. 
Antibodies were diluted in TBST containing 5% milk (Carl Roth) and incubated at 
4°C overnight on a shaker. Actin as a loading control was detected via an actin-
horseradish peroxidase (HRP) antibody (Santa Cruz Biotechnology (Catalog No. 
#sc47778). Detection of proteins was performed via HRP-conjugated anti-mouse anti-
rabbit antibodies (Millipore) via enhanced chemiluminescence (ECL) reagent (GE 
Healthcare) or via near infrared fluorescent dye coupled antibodies (LI-COR 
Biosciences). Due to overlapping molecular weights not all proteins were detected at 
the same membrane per displayed figure panel. 
 
Cell culture 
LC-2/AD cells were obtained from Sigma Aldrich. TPC-1 cell line was a kind gift 
from Dr. William Pao. Ba/F3 murine pro-B-cell line was a kind gift from Nikolas von 
Bubnoff. NIH-3T3 murine fibroblast cell line was purchased from DSMZ. All cell 
lines were grown in a humidified incubator at 37°C and 5% CO2 in the corresponding 
recommended media supplemented with antibiotics and fetal calf serum. 
 
Viability and Colony formation assays 
3,000 (adherent) or 10,000 cells (suspension) for viability assays in 96-well plates and 
10,000 cells for colony formation assays in 12-well plates were used and analyzed as 
previously described (38). GI50-values were determined with GraphPad Prism 6.0h. 
 
Molecular cloning and viral transduction 
Full length KIF5B-RET and CCDC6-RET were cloned in the retroviral vector pBabe-
puro (Addgene #1764) via Gibson assembly (NEB). KRAS-G12V was cloned via 
Gibson Assembly into the pLenti6 backbone (Thermo Scientific™). Site-directed 
mutagenesis was performed using Q5® polymerase (NEB). Mutations and analysis of 
complete inserts were confirmed via Sanger sequencing at the Cologne Center for 
Genomics. pBabe and pLenti vectors were co-transfected with corresponding helper 
plasmids with TransIT-LT1 (Mirus) using standard procedures in HEK293T cells. 
After several passages we observed a decrease in fitness of KRASG12V transduced LC-
2/AD cells. 
 
Undirected mutagenesis  
The cDNAs of CCDC6-RET and KIF5B-RET were cloned into the pBabe puro 
backbone. Undirected mutagenesis was performed via E. coli XL1-Red (Stratagene) 
bacteria cells for 24/48/72h as previously described (23, 24). After viral transductions 
in Ba/F3 cells, cells were challenged with 200nM AD80. After outgrowth, genomic 
DNA was isolated and sequenced using capture-based sequencing (CAGE) at NEO 
oncology.  
 
FISH 
Tumor specimens were stained with KIF5B and RET break-apart FISH probes were 
purchased from Zytovision. Per case 100 carcinoma cells were analyzed for 
rearrangements. Positivity was defined as ≥ 20% of cells showing aberrant patterns 
indicative of KIF5B- / RET-rearrangements: i) One break-apart (isolated red and 
isolated green signal) and one or more fusion signals ii) One or more isolated green 
signals and one or more fusion signals. 
 
Phosphoproteomal analysis 
Materials 
If not mentioned otherwise chemicals were purchased from Sigma Aldrich in the 
highest purity available. ULC-MS acetonitrile (ACN), formic acid (FA) and 
trifluoroacetic acid (TFA) were from Biosolve BV. Ultra-pure water was obtained 
from an ELGA Purelab flex water purification system (ELGA Labwater). C18 solid 
phase extraction was conducted using SPEC C18-AR cartridges (Agilent 
Technologies). 
Proteomics sample preparation 
Protein concentrations of cell lysates were determined by a Pierce bicinchinonic-acid 
assay kit (Themo Fisher Scientific) according to the manufacturer’s instructions. To 
degrade DNA samples were treated with 25U Benzonase® (Merck) in the presence of 
2mMmgCl2 and incubated at 37°C for 30min. Cysteins were reduced with 10mM 
dithiothreitol (DTT) for 30min at 56°C. Afterwards, free cysteines were alkylated 
with 30mM iodoacetamide (IAA) for 30min at RT in the dark. Excess IAA was 
quenched by addition of 10mM DTT for 15min. Proteolytic digestion was conducted 
using a modified filter aided sample preparation procedure (41): Per sample 150µg of 
protein was diluted with freshly prepared 8M urea, 100mM TRIS buffer (pH 8.5) to a 
final concentration of 7mM SDS and 6.4M urea (42). Samples were passed over 
30kDa Pall Nanosep Omega molecular weight cut off centrifuge filters (VWR 
International) by centrifugation for 25min at 13,500g, followed by three washing 
steps with 8M Urea, 100mM TRIS, pH 8.5 and another three steps with 50mM 
triethylammonium bicarbonate buffer (TEAB, pH 8.5). Trypsin (sequencing grade 
modified, Promega) was added in a 1:25 ratio in 150µL of 50mM TEAB, 0.2M 
guanidine hydrochloride and 2mM CaCl2 and samples were incubated at 37°C for 
14h. Generated peptide mixtures were collected from the filters by centrifugation, 
followed by two washing steps with 50µL of 50mM TEAB and H2O, respectively. 
Samples were acidified to pH ~2.0 with TFA and 1µg per sample was used to control 
digest efficiency and reproducibility as described elsewhere (43). 
TMT-labelling, multiplexing and sample cleanup: 
A mixed sample containing 150µg of peptide was generated using equal amounts of 
the 9 different conditions. Afterwards, 150µg per sample were labeled with TMT 10-
plex reagents (Thermo Fischer GmbH) according to the manufacturer’s protocol 
(controls: 126, 127N, 127C; 10nM AD80: 128N, 128C, 129N; 100nM AD80: 129C, 
130N, 130C; mixed sample: 131). After labeling and quenching with 5% 
hydroxylamine, samples were multiplexed, dried under vacuum and reconstituted in 
300µL of 0.1% TFA. Next, samples were desalted on a 50mg SPE cartridge and an 
aliquot corresponding to 40µg of peptides was taken for global proteome analysis (see 
below). 
Phosphopeptide enrichment and fractionation 
Phosphopeptides were enriched by TiO2 as described by Engholm-Keller et al. with slight 
modifications (44). Briefly, the multiplexed sample was incubated in 5% TFA, 80% 
ACN, 1M glycolic acid together with an excess of TiO2 beads for 3 times (beads to 
peptide ratios were 1:6, 1:3 and 1:1.5), and peptides were eluted from the beads with 
1.12% NH4OH. A second sequence of incubations with the same amounts of fresh 
TiO2 beads in 70% ACN, 2% TFA was performed to achieve maximum enrichment 
specificity. The phosphopeptide-enriched sample was desalted using Oligo R3 
(Applied Biosystems) (39). Phosphopeptides were reconstituted in HILIC loading 
buffer (98% ACN, 0.1% TFA) and directly fractionated by hydrophilic interaction 
liquid chromatography (HILIC) on an Ultimate 3000 RSLCnano system (Thermo 
Fisher Scientific) equipped with a self-packed 250µM x 15cm column filled with 
TSK GelAmide 80 material (3µM, 100Å, Tosoh Bioscience GmbH, Stuttgart, 
Germany). A 37min gradient from 10-35% of 0.1% TFA was used to obtain a total of 
16 fractions for LC-MS/MS analysis.  
High-pH reversed phase fractionation: 
For the global proteome analysis, 40µg of labeled peptides were fractionated by high 
pH RP chromatography using an UltiMate 3000 HPLC (Thermo Fisher Scientific). 
The peptide sample was redissolved in 10mM ammonium formate (pH 8.0, adjusted 
with FA) and separated on a BioBasic C18 column (500µM x 15cm, 5µM, 300Å, 
Thermo Fisher Scientific) with a flowrate of 12.5µL/min at 30°C using a gradient 
from 3-50% of 10mM ammonium formate, 84% ACN, pH 8.0 in 70min. Fractions 
were collected between 10-80min in concatenation mode (1min intervals) to yield a 
total of 20 fractions. Fractions were dried under vacuum and reconstituted in 32µL of 
0.1% TFA, 50% per fraction were subjected to LC-MS/MS analysis. 
Nano LC-MS/MS analysis 
Nano LC-MS/MS was conducted on an Ultimate 3000 RSLCnano system equipped 
with Acclaim PepMap C18 columns (precolumn: 100µM x 2cm, 5µM, 100Å; main 
column: 75µm x 50cm, 3µM, 100Å; both Thermo Scientific). Samples were 
reconstituted in 0.1% TFA and trapped on the precolumn for 10min at a flowrate of 
20µL/min 0.1% TFA. Peptides were separated using a binary gradient and solvents A 
(0.1% FA) and B (84% ACN, 0.1% FA) ranging from 3-35% B in either 60min 
(phospho) or 90min (global and phospho). The HPLC was online connected to a Q-
Exactive HF mass spectrometer (Thermo Fisher Scientific) via a nano-ESI interface in 
positive ion mode and samples were analyzed in data dependent acquisition mode 
(DDA). Survey scans were acquired with a resolution of 60,000, an AGC target value 
of 1 x 106 and a maximum injection time of 120ms. The top 15 most intense signals 
with charge states 2-5 were subjected to MS/MS using dynamic exclusion of 30s, an 
isolation width of 0.8m/z, an NCE of 33%, a resolution of 60,000, an AGC target 
value of 2 x 105 and a maximum injection time of 200ms, with the first mass set to 
100m/z. To compensate for a higher complexity of the global proteome fractions, the 
isolation width was reduced to 0.4m/z to reduce the potential precursor co-isolation. 
Data analysis: 
All raw files were searched against the human Swiss-Prot database 
(www.Uniprot.org; April 2016, 20,207 target sequences) using Mascot v 2.4.1 
(Matrix Science) and the Proteome Discoverer 1.4 software package (Thermo Fisher 
Scientific). Search settings were as follows. Trypsin was used as enzyme with a 
maximum of 2 missed cleavage sites. Mass tolerances were 10ppm for precursors and 
0.02Da for fragment ions. TMT 10-plex (+229.163Da on Lys and N-termini) and 
carbamidomethylation of Cys (+ 57.021Da) were set as static modifications. 
Phosphorylation of Ser/Thr/Tyr (+ 79.966Da) and oxidation of Met (+ 15.995Da) 
were set as dynamic modifications. Phosphorylation site confidence was determined 
using phosphoRS 3.1 and false discovery rate assessment was performed using 
Percolator (45, 46). For the phosphopeptide data analysis, only unique peptide-
spectrum-matches (PSMs) with high confidence (< 1% FDR), a search engine rank of 
1 and a minimum phosphoRS site localization probability of 0.9 for all sites were 
considered. For the global proteome only proteins quantified with at least 2 unique 
high confidence peptides were considered. Sorting and evaluation of the exported data 
as well as calculations were done in Microsoft Excel 2013.  
 
Global proteome: As Proteome Discoverer only provided 9 ratios for the 10 samples, 
an artificial 126/126 ratio was created and set to 1.0 per protein. For each channel a 
median over all protein log2-ratios was calculated (MD1126-131). Next, the median 
over all ten MD1 values was determined (MD2) to define normalization values (NV) 
per channel and these MD2 were subtracted from the individual MD1 values. This 
normalization was performed to compensate for individual systematic errors (i.e. 
unequal sample amounts derived from pipetting errors or inaccurate BCA results) and 
to obtain normalized log2-ratios (NR) per protein (126/126, 127/126, …, 131/126).  
Next, for each protein the median over all ten NRs was subtracted from the individual 
NRs to obtain scaled normalized abundance values (NAV) for all proteins and 
channels after retransformation to decadic values.  
 
Per protein NAVs of the three biological replicates were summed and used to obtain 
protein ratios between different conditions (e.g for 10nM AD80 vs. control: sum 
(128N,128C,129N)/sum(126,127N,127C)). Additionally, a Student’s t-test (two sided, 
homoscedastic) was applied between the respective triplicate groups of NAVs for 
each comparison. 
The global median (GM) and the global standard deviation (GSD) over all log-2 
protein ratios were then calculated for each comparison and values greater than GM + 
3*GSD or smaller than GM - 3*GSD were considered as potentially regulated, if the 
corresponding p-value was < 0.05.  
Phosphoproteome: The NVs, GMs and GSDs from the global proteome were used to 
process the phosphoproteomics data. First, for each TMT channel the areas of all 
PSMswere divided by their respective NVs to yield normalized areas (NAs). The NAs 
for each PSM were then scaled by dividing them by the median over all ten NAs to 
yield the normalized abundance values of phosphopeptide-PSMs (p-NAVs). The p-
NAVs of multiple PSMs corresponding to a specific phosphopeptide (same sequence, 
same phosphorylation site(s)) were averaged for each channel to obtain the averaged 
normalized abundance values of phosphopeptides (p-NAVavr). The p-NAVavrs were 
used to obtain ratios between biological conditions and corresponding p-values were 
determined as above. The ratios were subsequently log2-transformed. A 
phosphopeptide was considered as potentially regulated between conditions, if (i) the 
log2 ratio was greater than GM + 3*GSD or smaller than GM - 3*GSD; (ii) the 
corresponding p-value between was <0.05, (iii) the corresponding protein was not 
regulated in the global proteome data to ensure, that an apparent phosphorylation site 
regulation is not rather a change of expression during the 4h stimulation experiment.  
 
For computational prediction of kinases with altered activity from the differentially 
regulated phosphorylation sites observed in the phosphoproteome we used the group 
based kinase prediction algorithm (GPS) version 2.1.2 by Xue et al. (47). The FASTA 
formatted sequences of proteins with regulated phosphorylation sites were provided to 
GPS (high confidence threshold) for kinase prediction. Per site only the highest 
ranking high confidence kinase prediction was considered and the altered 
phosphorylation sites per kinase were quantified. 
 
Protein Thermal Shift assay 
Constructs 
Constructs were prepared as described previously (17). In addition, ΔCCDC6-KD 
(residues 54 to 101 fused to RET 713 to 1012) and ΔKIF5B-KD (residues 544 to 757 
fused to RET 713 to 1012) both including the D874N mutation to generate kinase 
dead constructs were ordered from Geneart (Life Technologies). Baculovirus 
production was carried out in the same manner as previously described (17). 
 
Protein Production 
SF21 cells were grown in SF-900 III SFX media with 10µg/ml gentamycin in shaker 
flasks at 27°C for protein production. Viral infections were performed on high density 
cells (5 x 106 cells/ml) supplemented with 1% glucose (Sigma), 6.64g/L yeastolate 
(Difco) and lactalbumin (Sigma). Cells were harvested 72 hours post-infection, 
resuspended in lysis buffer (20mM Tris pH 8.0, 150mM NaCl, 1mM DTT, 10mM 
Benzamidine, 0.2mM AEBSF), lysed by sonication and purified by incubation with 
glutathione-Sepharose 4B beads (Amersham Biosciences). Purified proteins were 
either dephosphorylated using 10 units of CIP (NEB) and 10mM MgCl2, or the core-
KD and JM-KD were phosphorylated with 2.5mM ATP and 10mM MgCl2. The 
immobilised ΔKIF5B-KD and ΔCCDC6-KD proteins were phosphorylated using 
purified solubilised JM-KD, 2.5mM ATP and 10mM MgCl2. Dephosphorylation and 
phosphorylation steps were all carried out for either 2 hours at RT or overnight at 4°C. 
Proteins were subsequently washed and cleaved from resin using a GST-linked 3C 
protease. Purified ΔKIF5B-KD and ΔCCDC6-KD proteins were additionally purified 
by size exclusion chromatography on a Superdex 200 column and all proteins were 
concentrated in HEPES buffer (20mM HEPES pH 8.0, 150mM NaCl and 1mM DTT) 
to 0.1mg/ml. 
 
Protein Thermal Shift  
Control or drug treatments were incubated with DMSO or indicated drug at a final 
concentration of 1 µM both to a final DMSO concentration of 1% and incubated for 
up to 30 minutes on ice. Sypro-Orange dye (Life Technologies) was subsequently 
added and incubated. Quadruplicates of each sample per experiment were set up in 
MicroAmp Fast Optical 96-Well Reaction Plates (Applied Biosystems) and plates 
were sealed and run in a 7500 Fast RT PCR machine (Applied Biosystems) with a 
temperature range of 25 – 90°C. Data was analysed using the Protein Thermal Shift 
Software v1.2 (Applied Biosystems). Derivative melt curve plots were used for final 
data analysis to generate the proteins melting point (Tm) and the difference in melting 
temperatures (ΔTm). Results were then averaged across experiments and SEM values 
were calculated.  
 
Computational binding mode modeling 
Similar to the initial steps in (19), we selected VEGFR (pdb code 2OH4 (18)) as 
template for modeling the relevant part of the wt RET protein due to the large 
sequence identity and availability of the DFG-out structure. Filling of sequence gaps 
and structure preparation was done using Modeller 9.14 (48). An initial estimate of 
the wt binding mode for AD80 was created by superimposing the chemically 
equivalent part of AD80 with the GIG ligand as provided in the template structure 
file. Because to the best of our knowledge no cabozantinib structure bound to a kinase 
domain is deposited in the PDB we generated an initial binding pose of cabozantinib 
to RET (wt) in a similar manner based on the final RET/AD80 model (see below). For 
that purpose we took the chemically equivalent part of the XL880 ligand bound to the 
c-Met kinase (PDB code 3LQ8) and superimposed it onto the RET(wt)/AD80 
complex followed by converting XL880 to cabozantinib. Two reasonable conformers 
of the quinoline ring system were initially created and the energetically favorable 
geometry was selected after energy minimization in an implicit water model 
environment (ALPB) (49). While Amber ff99sb (50) was chosen as the protein force 
field, we followed closely the preparation procedure outlined recently for the 
(assumed neutral) ligand models (51).  
All-atom molecular dynamics (MD) simulations for the RET complexes were 
performed by immersing them in 25428 (AD80) and 27987 (cabozantinib) TIP3P (52) 
water molecules after neutralizing with 8 chloride counterions employing NAMD 
2.10 (53) at a temperature of 298.15K using a time step of 2 fs. MD runs were 
conducted in a sequence of steps to ensure stability. An initial 4 ns were performed in 
the canonical ensemble applying harmonic restraints on protein Cα atoms and the 
ligand, followed by restrained 4ns in the isothermal-isobaric ensemble at 1 bar 
pressure to relax the volume. After lifting all restraints, additional 92 ns were 
simulated in the isothermal-isobaric ensemble. We checked the stability of these 
completely free systems by monitoring root mean square deviations (RSMD, Fig. 
S4A) from the initial structure, indicating sufficient stability. The resulting snapshot 
was optimized under ALPB conditions in Amber 12,(50) followed by point mutation 
by Modeller (54) to generate the V804M mutant. This structure was refined using a 
similar simulation protocol as for the wt, followed again by ALPB optimization. The 
initial structure for the RET(wt)/cabozantinib model was built based on the last frame 
of the RET(wt)/AD80 simulation, followed by further 112ns of isothermal-isobaric. 
The resulting snapshot was then treated in the same way as the RET/AD80 
complexes.  
The end point of the RET/AD80 simulation was used as starting point for 
thermodynamic integration (TI) MD simulations which were performed with pmemd 
in Amber 12 (50). This was done in order to estimate the binding free energy 
difference between AD80 and AD57 in the presumed DFG-out bound protein 
conformation, which differ only by a single atom (F in AD80 is alchemically 
transformed to H in AD57). Using MD settings as before, 11 consecutive coupling 
parameter (𝜆𝜆) windows (𝛿𝛿𝛿𝛿 = 0.1, 10 ns within each window) were simulated, 
dropping the initial 3 ns per window and using the remaining 7 ns for averaging in the 
isothermal-isobaric ensemble. To assure correct physics, the transformed hydrogen 
atom of AD57 was excluded from the bond constraint algorithm. 
In order to (roughly) estimate the binding free energy difference for AD80 bound to 
wt RET and to the V804M mutant, we performed single-state 3D RISM calculations 
on the final optimized structures, we essentially follow the methodology described in 
(40, 55-57). Briefly, the optimized complex partners were separated, keeping their 
internal geometries fixed. Independent 3D RISM calculations were performed in an 
aqueous environment (cubic grids of 3403 points with 0.3 Å spacing, second order 
partial series expansion closure, 298.15K, TIP3P water model parameters and 
conditions as in Ref. (57)) in order to yield the solvation free energies of the complex 
and the individual partners (40, 57). Applying this procedure for 10 ALPB-optimized 
snapshots taken every 1 ns from the last available frames of RETwt/AD80, 
RETwt/AD57, and RETV804M/AD80 simulations and adding the direct interaction 
energy of the complex partners yields a “per snapshot” estimate of the binding free 
energy. These values enter a discrete canonical partition function expression by 
Boltzmann weighting, from which the final estimates of the ensemble binding free 
energy difference were computed. These	can	be	compared	to	experimental	values	
via	–RT	ln	IC50(educt)/IC50(product),	RT	being	the	product	of	molar	gas	constant	
and	temperature. 
 
RNA sequencing 
RNA was isolated from duplicates of LC-2/AD cells following 48h treatment with 
100 nM AD80 or DMSO controls using the RNeasy Kit (Qiagen) following the 
manufacturers’ protocols. RNA quality and integrity was verified using a Tapestation 
(Agilent Technologies). Strand specific libraries were prepared using the TruSeq® 
Stranded mRNA sample preparation Kit. Library preparation started with 1µg total 
RNA. After poly-A selection (using poly-T oligo-attached magnetic beads), mRNA 
was purified and fragmented using divalent cations under elevated temperature. The 
RNA fragments underwent reverse transcription using random primers. This is 
followed by second strand cDNA synthesis with DNA Polymerase I and RNase H. 
After end repair and A-tailing, indexing adapters were ligated. After purification, 10ul 
template was used for amplification (14 PCR cycles) to create the final cDNA 
libraries. After library validation and quantification (Agilent 2100 Bioanalyzer), 
equimolar amounts of library were pooled. The pool was quantified by using the 
Peqlab KAPA Library Quantification Kit and the Applied Biosystems 7900HT 
Sequence Detection System. The pool was sequenced by using a HiSeq® 3000/4000 
PE Cluster Kit and a HiSeq® 3000/4000 SBS Kit on an Illumina HiSeq 4000 
sequencer with a paired- end  (76x7x76 cycles) protocol. Reads were mapped to the 
hg19 reference genome with TopHat and to genomic features according to the 
Illumina iGenomes hg19 gene annotation with the GenomicsFeatures v1.22.13 
package (58, 59). Differential expression analysis was performed using DESeq2 
v1.10.1 with standard parameters (except for independentFiltering=F) (60). q-values 
were calculated from raw p-values by Benjamini-Hochberg FDR adjustment for 
multiple testing. 
 
Gene set enrichment analysis 
Genes were ranked based on the log fold change divided by the standard error of the 
log fold change to incorporate both direction and significance of treatment effects. To 
analyze effects on MAPK signaling ranked lists were input into the GSEA Java 
application pre-ranked tool and queried against gene sets including genes down-
regulated (HALLMARK_KRAS_SIGNALING_DN) or genes up-regulated 
(HALLMARK_KRAS_SIGNALING_UP) by KRAS activation as defined by the 
Hallmark gene sets (27, 61, 62). Genes contributing most to the enrichment score 
(core enrichment) were recorded and visualized. 
 
Kinase selectivity score 
To quantify the cytotoxic selectivity of compounds we calculated a compound’s cell 
line selectivity similar to the kinase selectivity score approaches proposed by Davis et 
al. and Karaman et al. (63, 64). To this end we defined the genotype of the most 
sensitive cell line per compound as the main target and termed the corresponding 
concentration the primary GI50. In all cases the altered gene of the most sensitive cell 
line was among the intended targets of respective inhibitors. Similar to the concept of 
a ‘therapeutic window’ we then calculated for each compound the ratios of the other 
cell lines’ GI50’s to the primary GI50 to estimate which fold-increase of concentration 
relative to the primary GI50 is possible before growth of cell lines with other 
genotypes is impaired. This analysis showed that the GI50 concentrations of 
compounds with known high selectivity such as BGJ398 and ceritinib could be 
increased by 94-fold and 230-fold, respectively, before viability of a second cell line 
was decreased by 50% (Fig. S2A,B). In contrast, for the known multi-kinase 
inhibitors vandetanib and cabozantinib effects across other cell lines were already 
present at much lower ratios (Fig. S2A,B). 
 
Clustering of cell lines based on drug sensitivity 
For visualization cell lines were clustered based on GI50 values and depicted as a 
heatmap indicating compound sensitivities and genotypes. 
 
Statistical analyses 
All statistical analyses were performed using Microsoft Excel 2011 or GraphPad 
Prism 6.0h for Mac or R (https://www.r-project.org/). P-values were assessed using 
Student’s t-test unless specified otherwise. Significance is marked with * p-value ≤ 
0.05, ** p-value ≤ 0.01 or *** p-value ≤ 0.001. 
	 	
Supplemental Figures 
 
Fig. S1. Selective inhibition of signaling induced by rearranged RET. 
A) Ba/F3 cells expressing CCDC6-RETwt were treated (72h) at increasing doses of 
AD80, PF06463922 (PF06), regorafenib (REG), crizotinib (CRI), sorafenib (SOR), 
ponatinib (PON), vandetanib (VAN), ceritinib (CER) or cabozantinib (CAB) and the 
corresponding viability curves were assessed. B) The same setting was used in Ba/F3 
cells expressing KIF5B-RETwt in the presence of IL-3 is shown. C) The PCR product 
of the cDNA fusion transcript from NIH-3T3 cells with CRISPR/Cas9 induced 
KIF5B-RET fusion is displayed. Parental NIH-3T3 cells and Ba/F3 cells expressing 
KIF5B-RET serve as control. D) Chromatogram from Sanger sequencing of NIH-3T3 
cells with CRISPR/Cas9 induced KIF5B-RET fusion. E) Median cell number growth 
(up to 96h) from consecutive measurements ± SD (from n=3) comparing NIH-3T3 
cells and NIH-3T3 cells with CRISPR/Cas9 induced KIF5B-RET fusion. F) 
Immunoblot of Ba/F3 cells expressing myr-AKT under AD80 or vandetanib (VAN) 
treatment (4h).  
  
 Fig. S2. Characterization of the activity profile of AD80. 
A) Heat map of viability screening results from a panel of patient-derived cancer cell 
lines treated (72h) with AD80, alectinib (ALE), BGJ398 (BGJ), cabozantinib (CAB), 
ceritinib (CER), erlotinib (ERL), regorafenib (REG), vandetanib (VAN) or ponatinib 
(PON). Results are shown as average GI50 values (n=3). The main oncogenic drivers 
are shown in the upper panel: EGFR mutant/ MET amplification (PC9-GR), KRAS 
mutant (H441; H1792; A549; HCC44), HER2 overexpression (SKBR3; H1819), Her2 
mutant (H1781), FGFR1 amplification (H1581; H520), EML4-ALK fusion (H3122; 
H2228), EGFR mutant (H1975; PC9; HCC827), RET fusion (LC-2/AD; TPC-1) and 
unknown (H1568). B) Box plot of ratios between GI50 values of cell lines with 
respective primary genotypic targets and non-target cell lines screened against the 
panel of inhibitors. C) Volcano plot depicting log2-change of phosphorylation change 
plotted against the –log10 p-values from phosphoproteomic analyses. Among all 
detected phospho-peptides, receptor tyrosine kinases are highlighted in red. 
 
 
 
 Fig. S3. Delineation of the cellular targets of AD80 using ligand screens and 
thermal shift experiments and comparison of type I and II RET kinase 
inhibitors. 
A) Effects of growth factor supplementation on the viability of LC-2/AD cells treated 
with indicated compounds. Bars indicate average across concentrations and 
experiments, errorbars show 95% confidence intervals of the mean (from n=4) B) 
Schematic presentation of the constructs used in the thermal stability assay: core 
kinase domain (cKD), juxtamembrane-kinase domain (JM-KD), truncated ΔKIF5B-
KD and ΔCCDC6-KD fusions proteins. C) Coomassie stained SDS-PAGE gel of 
purified proteins: core kinase domain (cKD) 705-1012, juxtamembrane-kinase 
domain (JM-KD) 661-1012, Truncated ΔKIF5B-KD and ΔCCDC6-KD fusions 
proteins in a non-phosphorylated (NP) or phosphorylated (P) state. Molecular weight 
markers (kDa) are shown as indicated. D) Differences in melting temperatures from 
AD80, sorafenib (SOR), vandetanib (VAN), ponatinib (PON) or sunitinib (SUN) 
addition (ΔTm) and the respective standard errors of the mean (SEM) are shown for 
phosphorylated Core-KD. E) Overview of selected Type I kinase inhibitors and F) 
selected Type II kinase inhibitors with highlighted motifs addressing corresponding 
regions within the enzymes binding site. G) Vandetanib (Type I) in complex with 
RET kinase (PDB-entry: 2IVU) and H) AD57 (Type II) in complex with cSrc (PDB-
entry 3EL8). 
  
 Fig. S4. Root mean square deviations (RMSD) measurements of RET and AD80 
or cabozantinib and optimized structures after extensive MD refinement 
followed by ALPB optimization. 
A) Root mean square deviations (RMSD) of RET-wt (top, bottom) and RET-V804M 
(middle) with AD80 (top, middle) and Cabozantinib (bottom) over simulation time, 
measured from the starting point of the respective simulations (middle and bottom 
data have been started essentially at the final top panel geometry). B) RET-wt/AD57 
after 202 ns (92 ns from RET-wt/AD80 simulation followed by 110 ns TI-MD for 
gradually transforming AD80 into AD57, side view), (middle and lower panel) RET-
wt/Cabozantinib after 112 ns from different perspectives, the latter allowing for H-
bond identification. C) Superimposition of cSrc (brown, PDB code 3EL8) and RET-
wt (green) in complex with AD57 (see also Fig. 3CII). The experimentally resolved 
ligand pose is shown in light blue with phenylalanine of the DFG motif in orange. 
The corresponding MD results are shown in element-specific colors for AD57 and in 
violet for Phe of DFG. The DFG motif is shown in violet. Images have been created 
with PyMOL (The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, 
LLC). 
  
 Fig. S5. Inhibitory potential of AD80 derivatives and primary and secondary 
resistance against RET inhibition. 
A) Column chart of mean GI50-values + SD (from n≥3) of Ba/F3 cells expressing wild 
type and V804M mutated KIF5B-RET or CCDC6-RET after 72h of treatment with 
AD80 and AD80 derivatives AD57 and AD81. B) Column chart of mean GI50-values 
+ SD (from n≥3) of Ba/F3 cells expressing CCDC6-RETwt or CCDC6-RETV804M after 
72h of treatment as assessed for AD80, cabozantinib (CAB), vandetanib (VAN) and 
ponatinib (PON) is shown. C) Immunoblot of LC-2/AD cells under treatment with 
AD80 (0.1µM) for 1h, 6h, 24h and 48h. D) The same experimental setting was also 
applied to TPC-1 cells. E) Clonogenic assay of TPC-1 and LC-2/AD cells under 
treatment (7d) with either AD80 (0.5µM), trametinib (0.5µM) or a combination of 
both inhibitors. Cells are visualized via crystal violet staining. F) TPC-1 cells were 
treated (72h) with AD80 (0.5µM) trametinib (TRA) (0.5µM) or with a combination of 
both. Cellular viability was assessed and is given as mean % change from baseline.  
  
 Fig. S6. Validation of PDX via FISH and in vivo effects induced by treatment 
with AD80. 
A) An exemplary positive fluorescence in situ (FISH) break-apart analysis from mice 
engrafted with CCDC6-RET fusion positive patient-derived tumor tissue (CCDC6-
RETPDX) with split red and green signals is shown indicating RET gene 
rearrangements (white arrows). B) An equivalent FISH analysis from CCDC6-RET 
V804MPDX is shown. C) Median body weight change of CDDC6-RETPDX under 
treatment with AD80 (25 mg/kg) or vehicle control and 14 days of follow-up. D) The 
equivalent median body weight change for CCDC6-RET V804MPDX  is shown.  
  
 
Fig. S7. Limited clinical activity of currently available RET inhibitors and 
validation of a small cohort of patients with RET-rearrangements. 
A) Time of treatment for patients (P1-P4) that underwent therapy with either 
vandetanib (black), cabozantinib (rose) or sunitinib (light blue). B) Exemplary PET-
CT scans of Patient P2 (P2) showing best response of target lesions (left panel). 
Waterfall plots for best response of target lesions measured with PET/CT scans to 
vandetanib (black), cabozantinib (rose) or sunitinib (light blue) for each patient (right 
panel). PD: progressive disease; SD: stable disease; PR: partial response. C) 
Representative break-apart FISH (ba-FISH) images of KIF5B and RET probes for 
diagnostics of RET-rearrangements in patient P3. 
 
  
Supplemental Tables 
 
Table S1. IC50 values of AD80, cabozantinib and vandetanib for phospho-RET 
levels in Ba/F3 cells expressing wild type or V804M KIF5B-RET. 
Overview of IC50 values of phospho-RET signal from displayed immunoblots of 
Ba/F3 cells expressing wild type or V804M KIF5B-RET treated with AD80, 
cabozantinib and vandetanib. 
 
 
  
Table S2. GI50 values of the panel of patient-derived cell lines. 
A tabular overview of mean GI50 values (from n=3) from various patient-derived 
cancer cell lines treated (72h) with AD80, alectinib (ALE), BGJ398 (BGJ), 
cabozantinib (CAB), ceritinib (CER), erlotinib (ERL),ponatinib (PON), regorafenib 
(REG) or vandetanib (VAN) is shown. GI50 values are given in µM. 
 
 
  
Table S3. Tabulated derivative melting temperatures (Tm) and differences in 
melting temperature (ΔTm) values. 
Derivative melting temperatures (Tm) and differences in melting temperatures (ΔTm) 
values and the respective SEM variance are shown. Proteins were incubated with 1 
mM drug or equivalent volume of DMSO prior to experiment. Non-phosphorylated 
forms of each RET protein were extensively CIP-phosphatase treated to remove 
phospho-tyrosine. To activate the proteins, they were incubated either with Mg-ATP 
or with Mg-ATP and an active RET kinase protein to drive autophosphorylation. 
Thermal shift experiments were performed using between two and five independent 
preparations of each protein and were carried out in triplicates. 
 
 
  
Table S4. In vitro kinase assay of RET wt, V804M and V804L mutants with 
different inhibitors. 
An overview of IC50 values of a panel of type I and II RET inhibitors determined via 
homogeneous time-resolved fluorescence  (HTRF) in vitro kinase assay. 
 
 
  
Table S5. Experimental setup for saturated mutagenesis screening. 
An overview of the experimental setting for our saturated mutagenesis screening 
using XL1-RED E. coli is given. The primary RET construct transformed in XL1-
RED E. coli, the duration of accelerated mutagenesis in these cells, the AD80 
concentration at which transduced Ba/F3 cells were selected and the deep sequencing 
results are shown. 
 
 
  
Table S6. Clinical response rates to currently available anti-RET drugs and 
clinical information of patients used in retrospective analysis. 
A) Publically available clinical data for progression-free survival (PFS) and objective 
response rates (ORR) from patients with RET-rearranged tumors treated either with 
cabozantinib (NCT01639508; Drilon et al.) or vandetanib (Gautschi et al. and Yoh et 
al.) are displayed. B) Best response rates to targeted therapy for each patient receiving 
vandetanib, cabozantinib or sunitinib therapy relative to baseline are displayed. 
Response was annotated as “progressive response” (PR),  “steady disease” (SD) or 
“progressive disease” (PD) according to RECIST 1.1 criteria. The dosing of the 
individual drugs per patient is displayed. C) Overview of patients for RET-
rearrangement and detection method. 
	
 
	
	
